Xeljanz™ (tofacitinib) – Safety update
February 25, 2019 - The FDA announced that a safety study (A3921133) found an increased risk of pulmonary embolism and death when Pfizer's Xeljanz (tofacitinib) 10 mg twice daily was used in patients with rheumatoid arthritis (RA).
Download PDF
